Clinical trial
Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without…
NCT00433511 · National Cancer Institute (NCI), NIH · Active, not recruiting
Key facts
| NCT number | NCT00433511 |
|---|---|
| Title | Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer |
| Official title | A Double-Blind Phase III Trial of Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Bevacizumab or Placebo in Patients With Lymph Node Positive and High Risk Lymph Node Negative Breast Cancer |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Collaborators | Cancer and Leukemia Group B Eastern Cooperative Oncology Group North Central Cancer Treatment Group |
| Status | Active, not recruiting |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Breast Adenocarcinoma |
| Intervention type | Biological, Drug, Other |
| Interventions | Bevacizumab, Cyclophosphamide, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Paclitaxel, Placebo Administration, Quality-of-Life Assessment |
| Enrollment | 4,994 |
| Start date | Nov 2, 2007 |
| Primary completion | Jan 7, 2014 |
| Completion | Feb 22, 2026 |
| First posted | Feb 12, 2007 |
| Last update posted | Dec 3, 2025 |
| Countries | Peru, South Africa, United States |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: